Cargando…

PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer

BACKGROUND: The triple negative breast cancer (TNBC) paradox marks a major challenge in the treatment-decision making process. TNBC patients generally respond better to neoadjuvant chemotherapy compared to other breast cancer patients; however, they have a substantial higher risk of disease recurren...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Khadairi, Ghaneya, Naik, Adviti, Thomas, Remy, Al-Sulaiti, Boshra, Rizly, Shaheen, Decock, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317205/ https://www.ncbi.nlm.nih.gov/pubmed/30602372 http://dx.doi.org/10.1186/s12967-018-1757-3

Ejemplares similares

Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potential
por: Naik, Adviti, et al.
Publicado: (2021)

Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors
por: Naik, Adviti, et al.
Publicado: (2020)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer
por: Naik, Adviti, et al.
Publicado: (2019)

Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapy
por: Naik, Adviti, et al.
Publicado: (2021)

Editorial: Cancer testis antigens in cancer: Recent developments as cancer biomarkers and therapeutic targets
por: Naik, Adviti, et al.
Publicado: (2022)

PRAME expression and promoter hypomethylation in epithelial ovarian cancer
por: Zhang, Wa, et al.
Publicado: (2016)

Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
por: Thomas, Remy, et al.
Publicado: (2020)

The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition
por: Zapperi, Stefano, et al.
Publicado: (2023)

Cancer testis antigen expression in triple negative breast cancer: Candidate targets for cancer immunotherapy?
por: Hendrickx, Wouter, et al.
Publicado: (2015)

Novel Diphenylamine Analogs Induce Mesenchymal to Epithelial Transition in Triple Negative Breast Cancer
por: Bhatt, Akshita B., et al.
Publicado: (2019)

Intratumoral bidirectional transitions between epithelial and mesenchymal cells in triple‐negative breast cancer
por: Yamamoto, Mizuki, et al.
Publicado: (2017)

Classification of triple negative breast cancer by epithelial mesenchymal transition and the tumor immune microenvironment
por: Font-Clos, Francesc, et al.
Publicado: (2022)

NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling
por: Zhang, Jianchao, et al.
Publicado: (2016)

ESR2 Drives Mesenchymal-to-Epithelial Transition in Triple-Negative Breast Cancer and Tumorigenesis In Vivo
por: Piperigkou, Zoi, et al.
Publicado: (2022)

Intercellular Communication Reveals Therapeutic Potential of Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer
por: Liu, Yang, et al.
Publicado: (2022)

Transcription Factors: The Fulcrum Between Cell Development and Carcinogenesis
por: Islam, Zeyaul, et al.
Publicado: (2021)

Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells
por: Zhang, Yingzi, et al.
Publicado: (2021)

Identification of microRNA clusters cooperatively acting on epithelial to mesenchymal transition in triple negative breast cancer
por: Cantini, Laura, et al.
Publicado: (2019)

Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition
por: Garcia, Elizabeth, et al.
Publicado: (2021)

HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME)
por: Grillini, Marco, et al.
Publicado: (2022)

The Expansion of the PRAME Gene Family in Eutheria
por: Chang, Ti-Cheng, et al.
Publicado: (2011)

miR‐655 suppresses epithelial‐to‐mesenchymal transition by targeting Prrx1 in triple‐negative breast cancer
por: Lv, Zhi‐Dong, et al.
Publicado: (2016)

High expression of CD47 in triple negative breast cancer is associated with epithelial-mesenchymal transition and poor prognosis
por: Yuan, Jingping, et al.
Publicado: (2019)

A Six-Epithelial–Mesenchymal Transition Gene Signature May Predict Metastasis of Triple-Negative Breast Cancer
por: Wei, Li Yuan, et al.
Publicado: (2020)

Chemotherapeutic Stress Influences Epithelial–Mesenchymal Transition and Stemness in Cancer Stem Cells of Triple-Negative Breast Cancer
por: Li, Xiao, et al.
Publicado: (2020)

Effects of miR-93 on epithelial-to-mesenchymal transition and vasculogenic mimicry in triple-negative breast cancer cells
por: An, Gaili, et al.
Publicado: (2021)

Link between glucose metabolism and epithelial-to-mesenchymal transition drives triple-negative breast cancer migratory heterogeneity
por: Schwager, Samantha C., et al.
Publicado: (2022)

An androgen receptor regulated gene score is associated with epithelial to mesenchymal transition features in triple negative breast cancers
por: Rajarajan, Savitha, et al.
Publicado: (2023)

Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin
por: Wu, Ying-Min, et al.
Publicado: (2015)

GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer
por: Vijay, Geraldine Vidhya, et al.
Publicado: (2019)

Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors
por: Su, Yanrong, et al.
Publicado: (2018)

Tamoxifen reverses epithelial–mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells
por: Wang, Qian, et al.
Publicado: (2017)

GDF10 inhibits proliferation and epithelial-mesenchymal transition in triple‐negative breast cancer via upregulation of Smad7
por: Zhou, Tian, et al.
Publicado: (2019)

Curcumol enhances the anti-tumor effects of metformin via suppressing epithelial-mesenchymal transition in triple-negative breast cancer
por: Wang, Gangyue, et al.
Publicado: (2020)

IL-6 Impairs the Activity of Vitamin D(3) in the Regulation of Epithelial-Mesenchymal Transition in Triple Negative Breast Cancer
por: Abdel-Mohsen, Mohamed A., et al.
Publicado: (2019)

Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer
por: Koleckova, Marketa, et al.
Publicado: (2021)

Huaier polysaccharides suppress triple-negative breast cancer metastasis and epithelial-mesenchymal transition by inducing autophagic degradation of Snail
por: Tian, Yuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a3lav1i47qsg4bdkkoa1kqmgre